Perspective Therapeutics Stock Alpha and Beta Analysis
| CATX Stock | 2.84 0.03 1.07% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Perspective Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Perspective Therapeutics over a specified time horizon. Remember, high Perspective Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Perspective Therapeutics' market risk premium analysis include:
Beta (1.15) | Alpha (0.06) | Risk 5.73 | Sharpe Ratio (0.12) | Expected Return (0.70) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Perspective | Build AI portfolio with Perspective Stock |
Perspective Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Perspective Therapeutics market risk premium is the additional return an investor will receive from holding Perspective Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Perspective Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Perspective Therapeutics' performance over market.| α | -0.06 | β | -1.15 |
Perspective Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Perspective Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Perspective Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Perspective Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Perspective Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Perspective Therapeutics shares will generate the highest return on investment. By understating and applying Perspective Therapeutics stock market price indicators, traders can identify Perspective Therapeutics position entry and exit signals to maximize returns.
Perspective Therapeutics Return and Market Media
The median price of Perspective Therapeutics for the period between Sat, Oct 11, 2025 and Fri, Jan 9, 2026 is 2.73 with a coefficient of variation of 26.49. The daily time series for the period is distributed with a sample standard deviation of 0.75, arithmetic mean of 2.82, and mean deviation of 0.51. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | What margin trends mean for Perspective Therapeutics Inc. stock - Trade Signal Summary Safe Entry Trade Signal Reports - newser.com | 10/27/2025 |
2 | Perspective Therapeutics Q3 Earnings Snapshot | 11/10/2025 |
3 | Acquisition by Jonathan Hunt of 11000 shares of Perspective Therapeutics at 2.0268 subject to Rule 16b-3 | 11/13/2025 |
4 | Why Perspective Therapeutics Inc. stock could rally strongly - Market Volume Summary Low Risk Entry Point Guides - newser.com | 11/19/2025 |
5 | Acquisition by Johan Spoor of 6600 shares of Perspective Therapeutics at 3.8 subject to Rule 16b-3 | 11/21/2025 |
6 | Analyzing Perspective Therapeutics and TransEnterix | 12/01/2025 |
7 | Perspective Therapeutics and ReShape Lifesciences Head-To-Head Analysis | 12/10/2025 |
8 | Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | 12/18/2025 |
9 | Why Perspective Therapeutics Inc. stock remains a top recommendation - Bearish Engulfing Patterns These Stocks Are Just Getting Started - bollywoodhelpline.com | 12/29/2025 |
10 | NTS Acquires Vidterra, Expanding its Edge Software and Digital ISR Offerings | 01/07/2026 |
About Perspective Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Perspective or other stocks. Alpha measures the amount that position in Perspective Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2025 | 2026 (projected) | Days Sales Outstanding | 299.08 | 269.17 | 282.63 | PTB Ratio | 2.94 | 0.64 | 0.6 |
Perspective Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Perspective Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Perspective Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Perspective Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Perspective Therapeutics. Please utilize our Beneish M Score to check the likelihood of Perspective Therapeutics' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Perspective Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.